DAVENPORT & Co LLC lowered its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 16.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 151,045 shares of the biopharmaceutical company’s stock after selling 29,745 shares during the period. DAVENPORT & Co LLC’s holdings in Sangamo Therapeutics were worth $1,353,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of SGMO. Norges Bank acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth approximately $84,000. Cannell Peter B & Co. Inc. acquired a new position in shares of Sangamo Therapeutics in the first quarter worth approximately $65,000. Bedel Financial Consulting Inc. lifted its stake in shares of Sangamo Therapeutics by 1,538.5% in the first quarter. Bedel Financial Consulting Inc. now owns 10,650 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10,000 shares during the period. Investors Financial Group LLC acquired a new position in shares of Sangamo Therapeutics in the second quarter worth approximately $99,000. Finally, Pearl River Capital LLC acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth approximately $106,000. Institutional investors own 52.90% of the company’s stock.
SGMO has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. HC Wainwright lowered their target price on Sangamo Therapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Monday, June 22nd. BidaskClub upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 10th. Wedbush reiterated a “hold” rating and issued a $11.00 target price on shares of Sangamo Therapeutics in a report on Friday, June 19th. Finally, ValuEngine downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $11.50.
NASDAQ SGMO opened at $10.83 on Friday. Sangamo Therapeutics Inc has a 52 week low of $4.81 and a 52 week high of $12.49. The business has a 50 day moving average price of $10.22 and a 200-day moving average price of $8.71. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.98 and a current ratio of 5.98.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.14). The firm had revenue of $13.10 million for the quarter, compared to the consensus estimate of $22.73 million. Sangamo Therapeutics had a negative net margin of 89.31% and a negative return on equity of 22.68%. The company’s revenue was up 61.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.41) EPS. Equities research analysts forecast that Sangamo Therapeutics Inc will post -0.39 EPS for the current year.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Article: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.